As antibodies are expected to be present for a longer time than the virus as detected by PCR and follow a typical sequence of IgA, IgM and IgG positivity [10], such assays may help in estimating cumulative infection rates and shed light on asymptomatic infections to learn more about the actual disease burden of COVID-19. This evidence concerns the gene CD79A and COVID-19.